As IL‐33 stimulation also results in the production of GM‐CSF, IL‐5, and IL‐8 by MCs, which are crucial for eosinophil maturation and migration [99, 100], said evidence supports the use of dupilumab and/or anti‐IL‐33 antibodies for treating eosinophil‐high COPD by possibly blocking MC‐driven contribution to local eosinophil recruitment. Here, IL33 is linked to chronic obstructive pulmonary disease.